

Table 1: Patients characteristics and impact on 5-year OS and EFS.

	Number	%	OS	CI	P value	EFS	CI	P value
<u>Gender</u>								
Male	40	60%	60%	47-78	0.3	51%	38-70	0.4
Female	27	40%	71%	56-90		66%	50-87	
<u>Median age</u>	1.74 (0.2-10.1)							
<u>Age group</u>								
< 2 y	44	66%	57.8%	44.6 - 74.8	0.2	51%	38-69	0.03
>2 y	23	34%	78.3%	63.1 - 97.1		69%	52-91	
<u>Cytopenia</u>	20	30%	44%	26.2 - 72.6	0.02	31.0	15 - 62	0.05
<u>No cytopenia</u>	47	70%	73%	60.8 - 87.2		66.5	54 -82	
<u>Hepatic</u>	51	76%	56%	43-72	0.02	48%	36-64	0.03
<u>No hepatic</u>	16	24%	92%	77-100		83%	65-100	
<u>Splenomegaly</u>	45	67%	57%	44-74	0.1	47%	34-65	0.06
<u>No Splenomegaly</u>	18	33%	82%	77-100		77%	66-97	
<u>1st line</u>								
<u>LCH III</u>	20	30%	75%	58-97	0.5	75%	58-97	0.01
<u>VBL/ PREDs/IDMTX</u>								
<u>LCH IV</u>	47	70%	61%	48-77		49%	36-66	
<u>VBL/ PRED</u>								

CI: confidence interval, EFS event free survival, ID MTX: intermediate dose methotrexate, OS: overall survival, PRED: prednisone, VBL: vinblastine.